5ud9 › Citations

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.

Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H, Cesar Lorenzi JC, Halper-Stromberg A, Toth I, Piechocka-Trocha A, Gristick HB, van Gils MJ, Sanders RW, Wang LX, Seaman MS, Burton DR, Gazumyan A, Walker BD, West AP, Bjorkman PJ, Nussenzweig MC
Sci Transl Med 9 (2017)
Related entries: 5uel, 5uem

Cited: 83 times
EuropePMC logo PMID: 28100831

Abstract

Some HIV-1-infected patients develop broad and potent HIV-1 neutralizing antibodies (bNAbs) that when passively transferred to mice or macaques can treat or prevent infection. However, bNAbs typically fail to neutralize coexisting autologous viruses due to antibody-mediated selection against sensitive viral strains. We describe an HIV-1 controller expressing HLA-B57*01 and HLA-B27*05 who maintained low viral loads for 30 years after infection and developed broad and potent serologic activity against HIV-1. Neutralization was attributed to three different bNAbs targeting nonoverlapping sites on the HIV-1 envelope trimer (Env). One of the three, BG18, an antibody directed against the glycan-V3 portion of Env, is the most potent member of this class reported to date and, as revealed by crystallography and electron microscopy, recognizes HIV-1 Env in a manner that is distinct from other bNAbs in this class. Single-genome sequencing of HIV-1 from serum samples obtained over a period of 9 years showed a diverse group of circulating viruses, 88.5% (31 of 35) of which remained sensitive to at least one of the temporally coincident autologous bNAbs and the individual's serum. Thus, bNAb-sensitive strains of HIV-1 coexist with potent neutralizing antibodies that target the virus and may contribute to control in this individual. When administered as a mix, the three bNAbs controlled viremia in HIV-1YU2-infected humanized mice. Our finding suggests that combinations of bNAbs may contribute to control of HIV-1 infection.

Articles - 5ud9 mentioned but not cited (3)

  1. Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Barnes CO, Gristick HB, Freund NT, Escolano A, Lyubimov AY, Hartweger H, West AP, Cohen AE, Nussenzweig MC, Bjorkman PJ. Nat Commun 9 1251 (2018)
  2. Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Escolano A, Gristick HB, Gautam R, DeLaitsch AT, Abernathy ME, Yang Z, Wang H, Hoffmann MAG, Nishimura Y, Wang Z, Koranda N, Kakutani LM, Gao H, Gnanapragasam PNP, Raina H, Gazumyan A, Cipolla M, Oliveira TY, Ramos V, Irvine DJ, Silva M, West AP, Keeffe JR, Barnes CO, Seaman MS, Nussenzweig MC, Martin MA, Bjorkman PJ. Sci Transl Med 13 eabk1533 (2021)
  3. A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. Kumar S, Ju B, Shapero B, Lin X, Ren L, Zhang L, Li D, Zhou Z, Feng Y, Sou C, Mann CJ, Hao Y, Sarkar A, Hou J, Nunnally C, Hong K, Wang S, Ge X, Su B, Landais E, Sok D, Zwick MB, He L, Zhu J, Wilson IA, Shao Y. Sci Adv 6 eabb1328 (2020)


Reviews citing this publication (26)

  1. Recent progress in broadly neutralizing antibodies to HIV. Sok D, Burton DR. Nat Immunol 19 1179-1188 (2018)
  2. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Caskey M, Klein F, Nussenzweig MC. Nat Med 25 547-553 (2019)
  3. CD8+ T cells in HIV control, cure and prevention. Collins DR, Gaiha GD, Walker BD. Nat Rev Immunol 20 471-482 (2020)
  4. The science and medicine of human immunology. Pulendran B, Davis MM. Science 369 eaay4014 (2020)
  5. How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. Pancera M, Changela A, Kwong PD. Curr Opin HIV AIDS 12 229-240 (2017)
  6. Antibody-mediated prevention and treatment of HIV-1 infection. Gruell H, Klein F. Retrovirology 15 73 (2018)
  7. Monoclonal antibodies: technologies for early discovery and engineering. Kennedy PJ, Oliveira C, Granja PL, Sarmento B. Crit Rev Biotechnol 38 394-408 (2018)
  8. The expanding array of HIV broadly neutralizing antibodies. McCoy LE. Retrovirology 15 70 (2018)
  9. Passive and active antibody studies in primates to inform HIV vaccines. Hessell AJ, Malherbe DC, Haigwood NL. Expert Rev Vaccines 17 127-144 (2018)
  10. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. Ali MG, Zhang Z, Gao Q, Pan M, Rowan EG, Zhang J. Immunol Res 68 325-339 (2020)
  11. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? Subbaraman H, Schanz M, Trkola A. Retrovirology 15 52 (2018)
  12. HIV integration sites and implications for maintenance of the reservoir. Symons J, Cameron PU, Lewin SR. Curr Opin HIV AIDS 13 152-159 (2018)
  13. HIV vaccinology: 2021 update. Lee JH, Crotty S. Semin Immunol 51 101470 (2021)
  14. Antibody responses to the HIV-1 envelope high mannose patch. Daniels CN, Saunders KO. Adv Immunol 143 11-73 (2019)
  15. Coevolution of HIV-1 and broadly neutralizing antibodies. Doria-Rose NA, Landais E. Curr Opin HIV AIDS 14 286-293 (2019)
  16. Increasing the Clinical Potential and Applications of Anti-HIV Antibodies. Hua CK, Ackerman ME. Front Immunol 8 1655 (2017)
  17. Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies. Kreer C, Gruell H, Mora T, Walczak AM, Klein F. Vaccines (Basel) 8 E13 (2020)
  18. The Antibodiome-Mapping the Humoral Immune Response to HIV. Butler AL, Fischinger S, Alter G. Curr HIV/AIDS Rep 16 169-179 (2019)
  19. A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. Kwon YD, Asokan M, Gorman J, Zhang B, Liu Q, Louder MK, Lin BC, McKee K, Pegu A, Verardi R, Yang ES, Program VP, Carlton K, Doria-Rose NA, Lusso P, Mascola JR, Kwong PD. MAbs 13 1946918 (2021)
  20. Humanized Mice as a Tool to Study Sepsis-More Than Meets the Eye. Laudanski K. Int J Mol Sci 22 2403 (2021)
  21. Targeting the N332-supersite of the HIV-1 envelope for vaccine design. Moyo T, Kitchin D, Moore PL. Expert Opin Ther Targets 24 499-509 (2020)
  22. Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies. Sun Z, Yan L, Tang J, Qian Q, Lenberg J, Zhu D, Liu W, Wu K, Wang Y, Lu S. Virus Res 243 75-82 (2018)
  23. Perspectives on Non-BLT Humanized Mouse Models for Studying HIV Pathogenesis and Therapy. Terahara K, Iwabuchi R, Tsunetsugu-Yokota Y. Viruses 13 776 (2021)
  24. An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1. Kumar S, Singh S, Luthra K. ACS Omega 8 7252-7261 (2023)
  25. HIV-1 Envelope Glycosylation and the Signal Peptide. Lambert GS, Upadhyay C. Vaccines (Basel) 9 176 (2021)
  26. Engineering the supernatural: monoclonal antibodies for challenging infectious diseases. Grace PS, Gunn BM, Lu LL. Curr Opin Biotechnol 78 102818 (2022)

Articles citing this publication (54)

  1. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Escolano A, Gristick HB, Abernathy ME, Merkenschlager J, Gautam R, Oliveira TY, Pai J, West AP, Barnes CO, Cohen AA, Wang H, Golijanin J, Yost D, Keeffe JR, Wang Z, Zhao P, Yao KH, Bauer J, Nogueira L, Gao H, Voll AV, Montefiori DC, Seaman MS, Gazumyan A, Silva M, McGuire AT, Stamatatos L, Irvine DJ, Wells L, Martin MA, Bjorkman PJ, Nussenzweig MC. Nature 570 468-473 (2019)
  2. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Schoofs T, Barnes CO, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ. Immunity 50 1513-1529.e9 (2019)
  3. Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. Wagh K, Kreider EF, Li Y, Barbian HJ, Learn GH, Giorgi E, Hraber PT, Decker TG, Smith AG, Gondim MV, Gillis L, Wandzilak J, Chuang GY, Rawi R, Cai F, Pellegrino P, Williams I, Overbaugh J, Gao F, Kwong PD, Haynes BF, Shaw GM, Borrow P, Seaman MS, Hahn BH, Korber B. Cell Rep 25 893-908.e7 (2018)
  4. Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. Wang H, Gristick HB, Scharf L, West AP, Galimidi RP, Seaman MS, Freund NT, Nussenzweig MC, Bjorkman PJ. Elife 6 e27389 (2017)
  5. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. Mor M, Werbner M, Alter J, Safra M, Chomsky E, Lee JC, Hada-Neeman S, Polonsky K, Nowell CJ, Clark AE, Roitburd-Berman A, Ben-Shalom N, Navon M, Rafael D, Sharim H, Kiner E, Griffis ER, Gershoni JM, Kobiler O, Leibel SL, Zimhony O, Carlin AF, Yaari G, Dessau M, Gal-Tanamy M, Hagin D, Croker BA, Freund NT. PLoS Pathog 17 e1009165 (2021)
  6. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses. Kumar S, Panda H, Makhdoomi MA, Mishra N, Safdari HA, Safdari HA, Chawla H, Aggarwal H, Reddy ES, Lodha R, Kumar Kabra S, Chandele A, Dutta S, Luthra K. J Virol 93 e01495-18 (2019)
  7. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir. Mujib S, Liu J, Rahman AKMN, Schwartz JA, Bonner P, Yue FY, Ostrowski MA. J Virol 91 e00634-17 (2017)
  8. HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection. Rouers A, Klingler J, Su B, Samri A, Laumond G, Even S, Avettand-Fenoel V, Richetta C, Paul N, Boufassa F, Hocqueloux L, Mouquet H, Rouzioux C, Lambotte O, Autran B, Graff-Dubois S, Moog C, Moris A, ANRS CO21 Cohort. EBioMedicine 21 158-169 (2017)
  9. Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis. Watson A, Li H, Ma B, Weiss R, Bendayan D, Abramovitz L, Ben-Shalom N, Mor M, Pinko E, Bar Oz M, Wang Z, Du F, Lu Y, Rybniker J, Dahan R, Huang H, Barkan D, Xiang Y, Javid B, Freund NT. Nat Commun 12 602 (2021)
  10. Kappa chain maturation helps drive rapid development of an infant HIV-1 broadly neutralizing antibody lineage. Simonich CA, Doepker L, Ralph D, Williams JA, Dhar A, Yaffe Z, Gentles L, Small CT, Oliver B, Vigdorovich V, Mangala Prasad V, Nduati R, Sather DN, Lee KK, Matsen Iv FA, Overbaugh J. Nat Commun 10 2190 (2019)
  11. Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. Ringe RP, Cruz Portillo VM, Dosenovic P, Ketas TJ, Ozorowski G, Nogal B, Perez L, LaBranche CC, Lim J, Francomano E, Wilson IA, Sanders RW, Ward AB, Montefiori DC, Nussenzweig MC, Klasse PJ, Cupo A, Moore JP. J Virol 94 e01883-19 (2020)
  12. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies. Davis-Gardner ME, Alfant B, Weber JA, Gardner MR, Farzan M. mBio 11 e03080-19 (2020)
  13. Aerosol Delivery of Synthetic mRNA to Vaginal Mucosa Leads to Durable Expression of Broadly Neutralizing Antibodies against HIV. Lindsay KE, Vanover D, Thoresen M, King H, Xiao P, Badial P, Araínga M, Park SB, Tiwari PM, Peck HE, Blanchard EL, Feugang JM, Olivier AK, Zurla C, Villinger F, Woolums AR, Santangelo PJ. Mol Ther 28 805-819 (2020)
  14. Case report: mechanisms of HIV elite control in two African women. Moosa Y, Tanko RF, Ramsuran V, Singh R, Madzivhandila M, Yende-Zuma N, Abrahams MR, Selhorst P, Gounder K, Moore PL, Williamson C, Abdool Karim SS, Garrett NJ, Burgers WA. BMC Infect Dis 18 54 (2018)
  15. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. González N, McKee K, Lynch RM, Georgiev IS, Jimenez L, Grau E, Yuste E, Kwong PD, Mascola JR, Alcamí J. PLoS One 13 e0193773 (2018)
  16. Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates. Lorenzi JCC, Mendoza P, Cohen YZ, Nogueira L, Lavine C, Sapiente J, Wiatr M, Mugo NR, Mujugira A, Delany S, Lingappa J, Celum C, Seaman MS, Caskey M, Nussenzweig MC. J Virol 95 JVI.01909-20 (2021)
  17. A cross-neutralizing antibody between HIV-1 and influenza virus. Lee CD, Watanabe Y, Wu NC, Han J, Kumar S, Pholcharee T, Seabright GE, Allen JD, Lin CW, Yang JR, Liu MT, Wu CY, Ward AB, Crispin M, Wilson IA. PLoS Pathog 17 e1009407 (2021)
  18. Immunological Fingerprints of Controllers Developing Neutralizing HIV-1 Antibodies. Martin-Gayo E, Gao C, Chen HR, Ouyang Z, Kim D, Kolb KE, Shalek AK, Walker BD, Lichterfeld M, Yu XG. Cell Rep 30 984-996.e4 (2020)
  19. One-step CRISPR/Cas9 method for the rapid generation of human antibody heavy chain knock-in mice. Lin YC, Pecetta S, Steichen JM, Kratochvil S, Melzi E, Arnold J, Dougan SK, Wu L, Kirsch KH, Nair U, Schief WR, Batista FD. EMBO J 37 e99243 (2018)
  20. A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. Wang Z, Barnes CO, Gautam R, Cetrulo Lorenzi JC, Mayer CT, Oliveira TY, Ramos V, Cipolla M, Gordon KM, Gristick HB, West AP, Nishimura Y, Raina H, Seaman MS, Gazumyan A, Martin M, Bjorkman PJ, Nussenzweig MC, Escolano A. Elife 9 e61991 (2020)
  21. CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children. Kumar S, Kumar R, Khan L, Makhdoomi MA, Thiruvengadam R, Mohata M, Agarwal M, Lodha R, Kabra SK, Sinha S, Luthra K. Front Immunol 8 1568 (2017)
  22. Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. Lorin V, Fernández I, Masse-Ranson G, Bouvin-Pley M, Molinos-Albert LM, Planchais C, Hieu T, Péhau-Arnaudet G, Hrebík D, Girelli-Zubani G, Fiquet O, Guivel-Benhassine F, Sanders RW, Walker BD, Schwartz O, Scheid JF, Dimitrov JD, Plevka P, Braibant M, Seaman MS, Bontems F, Di Santo JP, Rey FA, Mouquet H. J Exp Med 219 e20212045 (2022)
  23. Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status. Lucar O, Su B, Potard V, Samri A, Autran B, Moog C, Debré P, Vieillard V. EBioMedicine 22 122-132 (2017)
  24. Current Treatment Options for HIV Elite Controllers: a Review. Promer K, Karris MY. Curr Treat Options Infect Dis 10 302-309 (2018)
  25. Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. Cizmeci D, Lofano G, Rossignol E, Dugast AS, Kim D, Cavet G, Nguyen N, Tan YC, Seaman MS, Alter G, Julg B. Elife 10 e62648 (2021)
  26. Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. Rossignol ED, Dugast AS, Compere H, Cottrell CA, Copps J, Lin S, Cizmeci D, Seaman MS, Ackerman ME, Ward AB, Alter G, Julg B. Cell Rep 35 109167 (2021)
  27. Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Willis JR, Berndsen ZT, Ma KM, Steichen JM, Schiffner T, Landais E, Liguori A, Kalyuzhniy O, Allen JD, Baboo S, Omorodion O, Diedrich JK, Hu X, Georgeson E, Phelps N, Eskandarzadeh S, Groschel B, Kubitz M, Adachi Y, Mullin TM, Alavi NB, Falcone S, Himansu S, Carfi A, Wilson IA, Yates JR, Paulson JC, Crispin M, Ward AB, Schief WR. Immunity 55 2149-2167.e9 (2022)
  28. Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. Swanson O, Rhodes B, Wang A, Xia SM, Parks R, Chen H, Sanzone A, Cooper M, Louder MK, Lin BC, Doria-Rose NA, Bonsignori M, Saunders KO, Wiehe K, Haynes BF, Azoitei ML. Cell Rep 36 109561 (2021)
  29. Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B' Infected Plasma Donor with Broadly Neutralizing Activity. Hu Y, Zou S, Wang Z, Liu Y, Ren L, Hao Y, Sun S, Hu X, Ruan Y, Ma L, Shao Y, Hong K. Vaccines (Basel) 9 311 (2021)
  30. Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers. Molinos-Albert LM, Lorin V, Monceaux V, Orr S, Essat A, Dufloo J, Schwartz O, Rouzioux C, Meyer L, Hocqueloux L, Sáez-Cirión A, Mouquet H, ANRS VISCONTI Study Group. Nat Commun 13 1944 (2022)
  31. A diverse collection of B cells responded to HIV infection in infant BG505. Simonich C, Shipley MM, Doepker L, Gobillot T, Garrett M, Cale EM, Hennessy B, Itell H, Chohan V, Doria-Rose N, Nduati R, Overbaugh J. Cell Rep Med 2 100314 (2021)
  32. Letter Association of HIV-1 Gag-Specific IgG Antibodies With Natural Control of HIV-1 Infection in Individuals Not Carrying HLA-B*57: 01 Is Only Observed in Viremic Controllers. Tjiam MC, Morshidi MA, Sariputra L, Martin JN, Deeks SG, Tan DBA, Lee S, Fernandez S, French MA. J Acquir Immune Defic Syndr 76 e90-e92 (2017)
  33. Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection. Shipley MM, Mangala Prasad V, Doepker LE, Dingens A, Ralph DK, Harkins E, Dhar A, Arenz D, Chohan V, Weight H, Mandaliya K, Bloom JD, Matsen FA, Lee KK, Overbaugh JM. Elife 10 e68110 (2021)
  34. HIV-1 Vpu restricts Fc-mediated effector functions in vivo. Prévost J, Anand SP, Rajashekar JK, Zhu L, Richard J, Goyette G, Medjahed H, Gendron-Lepage G, Chen HC, Chen Y, Horwitz JA, Grunst MW, Zolla-Pazner S, Haynes BF, Burton DR, Flavell RA, Kirchhoff F, Hahn BH, Smith AB, Pazgier M, Nussenzweig MC, Kumar P, Finzi A. Cell Rep 41 111624 (2022)
  35. Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)? Caskey M, Kuritzkes DR. Clin Infect Dis 75 S530-S540 (2022)
  36. Pharmaceutical Approaches to HIV Treatment and Prevention. Yavuz B, Morgan JL, Showalter L, Horng KR, Dandekar S, Herrera C, LiWang P, Kaplan DL. Adv Ther (Weinh) 1 1800054 (2018)
  37. A Quantitative Live-Cell Superresolution Imaging Framework for Measuring the Mobility of Single Molecules at Sites of Virus Assembly. Groves NS, Bruns MM, van Engelenburg SB. Pathogens 9 E972 (2020)
  38. Endocytosed HIV-1 Envelope Glycoprotein Traffics to Rab14+ Late Endosomes and Lysosomes to Regulate Surface Levels in T-Cell Lines. Hoffman HK, Aguilar RS, Clark AR, Groves NS, Pezeshkian N, Bruns MM, van Engelenburg SB. J Virol 96 e0076722 (2022)
  39. Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein. van Schooten J, Farokhi E, Schorcht A, van den Kerkhof TLGM, Gao H, van der Woude P, Burger JA, Meesters TGR, Bijl T, Ghalaiyini R, Turner HL, Dorning J, van Schaik BDC, van Kampen AHC, Labranche CC, Stanfield RL, Sok D, Montefiori DC, Burton DR, Seaman MS, Ozorowski G, Wilson IA, Sanders RW, Ward AB, van Gils MJ. Nat Commun 13 4515 (2022)
  40. A glycoside analog of mammalian oligomannose formulated with a TLR4-stimulating adjuvant elicits HIV-1 cross-reactive antibodies. Bruxelle JF, Kirilenko T, Trattnig N, Yang Y, Cattin M, Kosma P, Pantophlet R. Sci Rep 11 4637 (2021)
  41. B-cell restriction - an alternative piece to the puzzle. Gershoni JM. Hum Vaccin Immunother 15 2044-2049 (2019)
  42. Broad neutralization response in a subset of HIV-1 subtype C-infected viraemic non-progressors from southern India. Nandagopal P, Bhattacharya J, Srikrishnan AK, Goyal R, Ravichandran Swathirajan C, Patil S, Saravanan S, Deshpande S, Vignesh R, Solomon SS, Singla N, Mukherjee J, Murugavel KG. J Gen Virol 99 379-392 (2018)
  43. Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer. Lee JH, Nakao C, Appel M, Le A, Landais E, Kalyuzhniy O, Hu X, Liguori A, Mullen TM, Groschel B, Abbott RK, Sok D, Schief WR, Crotty S. Cell Rep 38 110485 (2022)
  44. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. Nyanhete TE, Edwards RJ, LaBranche CC, Mansouri K, Eaton A, Dennison SM, Saunders KO, Goodman D, Janowska K, Spreng RL, Zhang L, Mudrak SV, Hope TJ, Hora B, Bradley T, Georgiev IS, Montefiori DC, Acharya P, Tomaras GD. Front Immunol 12 670561 (2021)
  45. Antibodies: what makes us stronger. Freund NT. Hum Vaccin Immunother 17 3551-3553 (2021)
  46. Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies. Joyce C, Murrell S, Murrell B, Omorodion O, Ver LS, Carrico N, Bastidas R, Nedellec R, Bick M, Woehl J, Zhao F, Burns A, Barman S, Appel M, Ramos A, Wickramasinghe L, Eren K, Vollbrecht T, Smith DM, Kosakovsky Pond SL, McBride R, Worth C, Batista F, Sok D, IAVI Protocol C Investigators & The IAVI African HIV Research Network, Poignard P, Briney B, Wilson IA, Landais E, Burton DR. PLoS Pathog 19 e1011416 (2023)
  47. Comprehensive profiling of pre-infection antibodies identifies HIV targets associated with viremic control and viral load. Grant-McAuley W, Morgenlander W, Hudelson SE, Thakar M, Piwowar-Manning E, Clarke W, Breaud A, Blankson J, Wilson E, Ayles H, Bock P, Moore A, Kosloff B, Shanaube K, Meehan SA, van Deventer A, Fidler S, Hayes R, Ruczinski I, Kammers K, Laeyendecker O, Larman HB, Eshleman SH. Front Immunol 14 1178520 (2023)
  48. Cross-reactivity of glycan-reactive HIV-1 broadly neutralizing antibodies with parasite glycans. Huettner I, Krumm SA, Serna S, Brzezicka K, Monaco S, Walpole S, van Diepen A, Allan F, Hicks T, Kimuda S, Emery AM, IAVI Protocol C Investigators & The IAVI African HIV Research Network, Landais E, Hokke CH, Angulo J, Reichardt N, Doores KJ. Cell Rep 38 110611 (2022)
  49. Differing natural killer cell, T cell and antibody profiles in antiretroviral-naive HIV-1 viraemic controllers with and without protective HLA alleles. Moyano A, Ndlovu B, Mbele M, Naidoo K, Khan N, Mann JK, Ndung'u T. PLoS One 18 e0286507 (2023)
  50. Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning. Radford CE, Schommers P, Gieselmann L, Crawford KHD, Dadonaite B, Yu TC, Dingens AS, Overbaugh J, Klein F, Bloom JD. Cell Host Microbe 31 1200-1215.e9 (2023)
  51. Neutralization Sensitivity and Evolution of Virus in a Chronic HIV-1 Clade B Infected Patient with Neutralizing Activity against Membrane-Proximal External Region. Tang W, Yuan Z, Wang Z, Ren L, Li D, Wang S, Hao Y, Li J, Shen X, Ruan Y, Shao Y, Liu Y. Pathogens 12 497 (2023)
  52. Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time. Wang L, Liang S, Huang J, Ding Y, He L, Hao Y, Ren L, Zhu M, Feng Y, Rashid A, Liu Y, Jiang S, Hong K, Ma L. Front Cell Infect Microbiol 12 862754 (2022)
  53. Recognition determinants of improved HIV-1 neutralization by a heavy chain matured pediatric antibody. Kumar S, Singh S, Chatterjee A, Bajpai P, Sharma S, Katpara S, Lodha R, Dutta S, Luthra K. iScience 26 107579 (2023)
  54. Walking down the memory lane with SARS-CoV-2 B cells. Freund NT, Gerlic M, Croker BA. Immunol Cell Biol 99 796-799 (2021)


Quick links